Microbial attack on the brain has been suggested as a potential root-cause for dementia, including Alzheimer’s disease (AD), which is now the second leading cause of death in the UK. The defining diagnostic marker of AD is the presence of amyloid-β (Aβ) plaques in the brain. The precise physiological role of these plaques remains unclear, but recent work is suggesting a direct connection to bacterial infiltration of the brain. In this project you will explore the antimicrobial properties of Aβ peptides and determine their mechanisms of activity.
 Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, AN1792(QS-21)-201 Study Team (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553-1562.
 Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54
 Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase 3 Study, Group (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 302, 2557-2564.
 Kagan BL, Jang H, Capone R, Arce FT, Ramachandran S, Lal R, Nussinov R (2012) Antimicrobial properties of amyloid peptides. Mol. Pharmaceutics 9, 708-717.
 Gostzyla ML, Brothers HM, Robinson SR. (2018) Alzheimer’s Amyloid-β is an antimicrobial peptide: A review of the evidence. J. Alzheimers Dis. 62, 1495-1506.